Gilead’s antiviral drug, Remdesivir proves hopeful in Phase 3 trial
"Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir" Source: Gilead's News Gilead Sciences, Inc. (Nasdaq: GILD)...
"Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir" Source: Gilead's News Gilead Sciences, Inc. (Nasdaq: GILD)...
Source: Gilead Press Release "Remdesivir treatment resulted in clinical improvement in 68 percent of patients in this limited data set"...
"Remdesivir already in human trials in search for the treatment of deadly disease" Source: GILLIAN RUTHERFORD | University of Alberta...